EANS-News: november AG
Publication of consolidated financial results for 2009
/
Continued upswing of november AG
Köln (euro adhoc) -
improved operating profits despite reduced consolidated revenues consolidated results virtually break-even with EUR 0.3 mio reduction of liabilities from EUR 9.9 mio to EUR 6.9 mio increase of equity capital from EUR 7.9 mio (2007), EUR 5.6 mio (2008) to EUR 3.8 mio (2009) improved liquidity of EUR 0.7 mio
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
annual report/Annual Reports/annual result/Financial Figures/Balance Sheet
Subtitle: improved operating profits despite reduced consolidated revenues consolidated results virtually break-even with EUR 0.3 mio reduction of liabilities from EUR 9.9 mio to EUR 6.9 mio increase of equity capital from EUR 7.9 mio (2007), EUR 5.6 mio (2008) to EUR 3.8 mio (2009) improved liquidity of EUR 0.7 mio
The november group, essentially consisting of the november AG (holding) and the operating units PROGEN Biotechnik GmbH and Multimetrix GmbH, achieved consolidated sales renues of EUR 5.3 mio (previous year EUR 8.1 mio) despite the discontinuation of the Axis-Shield product line. Although sales revenues decreased due to the transfer of this product range, the consolidated operating results increased considerably from EUR -0.7 mio in 2008 to EUR -0.2 mio in fiscal year 2009. Thus, the restructuring of the november group also shows positive results in other important operative levels.
Same as previous year (EUR -0.2 mio), consolidated results nearly reached break-even in fiscal year 2009 with EUR -0.3 mio. This reflects the overall successful restructuring process of the november group as well as the focus of the operating units on high-margin products and profitable services. The consolidated financial results improved considerably as compared to the previous year. Due to continued restructuring of financial liabilities in 2009 and as a result of interest waivers, the financial results improved to EUR -0.1 mio in 2009 as compared to EUR -0.4 mio in 2008.
Liabilities were further decreased in 2009 as compared to the previous year (2009: EUR 6.9 mio, 2008: EUR 9.9 mio). Accordingly, the total equity increased considerably to EUR -3.8 mio as compared to previous years (2008: EUR -5.7 mio, 2007: EUR -7.9 mio). Additional measures were implemented already in the fist quarter of 2010 to further reduce liabilities of the group. For results and comments, please refer to the 1st quarter report 2010. For fiscal year ending December 31, 2009 the november group shows a liquidity of approx. EUR 0.7 mio despite significant loan repayments.
Please refer to the consolidated management report 2009 including all certified financial results under www.november.eu/company-profile/reports.html.
Presentation of corporate business results for fiscal year 2009 at the next annual general meeting of the november AG which is planned for July 21, 2010 in Cologne.
end of announcement euro adhoc
Further inquiry note:
Christoph Schmitz
Leiter Finanzen, Controlling
Tel.: +49 (0) 221- 820 05 20 -10
E-Mail: info@november.de
Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade